FDA approves First RSV vaccine for adults under 60

FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
CDC Panel Backs Expanded Use Of Pfizer's Pneumococcal Vaccine
Pfizer Inc. (PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.
FDA approves 1st RSV vaccine for adults under 60
The expansion builds on the previous indication for adults 60 years and older. The vaccine is also approved for pregnant individuals to protect infants from birth up to six months. With the decision,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
BioPharma Dive12h
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...
FiercePharma1d
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
CDC recommends second COVID vaccine dose for those 65 and older
Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
He Made Pfizer a Household Name. Wall Street Wants More.
With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...
CNET19d
Novavax Is Here for the COVID Fight: What to Know About the Vaccine
This means adults have a choice in which COVID vaccine they receive: an mRNA vaccine by Moderna or Pfizer, or Novavax, a protein-based vaccine that targets the virus in a more "traditional" ...
Reuters29d
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to ...